We previously performed a phase II trial of dovitinib, a novel TKI targeting c-KIT, fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR), and platelet-derived growth factor receptor β (PDGFRβ) for patients with TKI-refractory GISTs (Kang et al., Br J Cancer, 2013;109:2309).
Serum Protein Biomarkers
Pre-dose serum samples were collected on day 1 of cycle 1 (n=30) and cycle 2 (n=28) and ELISA was used to assess serum levels of each candidate protein biomarkers of anti-angiogenesis.
VEGF165 (Invitrogen, USA), VEGF-A (ebioscience, USA), soluble VEGFR (sVEGFR)-1, -2 (ebioscience), placental growth factor (PIGF; R&D, USA), interleukin-8 (IL-8; R&D), basic fibroblast growth factor (bFGF; Invitrogen) and FGF23 (Millipore, USA).
METHODS

BEAMing of ctDNA
Free circulating DNA was isolated from baseline serum samples using a QIAamp DNA purification kit (Qiagen).
BEAMing assays were performed on serum ctDNA samples for detection of 29 KIT mutations (5 in exon 11, 1 in exon 9, 2 in exon 13, 2 in exon 14, 18 in exon 17, and 1 in exon 18), 5 PDGFRα mutations, and 1 BRAF mutation. BEAMing assays were conducted by Inostics GmbH (Hamburg, Germany).
Serum Protein Biomarkers
At the end of first cycle, dovitinib significantly increased the levels of VEGF165 (1.26-fold), VEGF-A (1.27-fold), PIGF (6.0-fold), FGF23 (1.45-fold), and IL-8 (1.75-fold), whereas sVEGFR-2 levels decreased 0.8-fold from baseline.
Correlation between changes in sVEGFR-2, and metabolic response by PET-CT (A) and PFS (B), Q; quartile
RESULTS
Genotyping of ctDNA by BEAMing
Primary kinase mutation
Identified in five (17%) patients (two for KIT exon 11, and three for exon 9).
100% concordant with the results of mutation analyses from tumor tissue taken from the corresponding patients.
Secondary kinase mutation
Identified in 11 (37%) patients. All identified mutations involved KIT exon 17.
Three (27%) of these patients had more than one secondary KIT mutation. In two patients, additional mutations in other KIT exons were detected (each for exon 18, and exon 13). Different mutations of KIT exon 17 were simultaneously identified in two patients.
None of baseline characteristics was significantly associated with the presence of secondary mutations, except age (mutation detected vs not detected, 63 vs 54 years; p=0.01).
Correlation between clinical outcomes and secondary mutation
No significant correlation of secondary mutations with response rate, 24-week DCR, and metabolic response rate. However, all 4 patients who achieved disease control by 24 weeks had no secondary serum ctDNA mutations, whereas tumor progressed within 24 weeks in all patients with secondary mutations.
Secondary mutations had marginal relationship with poor PFS (A)
Median 3.4 months (95% CI, 2.2-4.6 months) vs. 4.2 months (95% CI, 2.8-5.6 months), HR=1.9 (95% CI, 0.8-4.5); p=0.11
Secondary mutations had significant relationship with poor OS (B)
Median 5.5 months (95% CI, 3.8-7.2 months) vs. 9.8 months (95% CI, 9.6-10.0 months), HR=3.1 (95% CI, 1.1-8.4); p=0.02 In patients with no secondary ctDNA mutations, no serum protein biomarkers correlated with PFS. Dovitinib has pharmacological effects on both the VEGFR and FGFR pathways.
Although baseline levels of candidate serum biomarkers were not predictive, changes in sVEGFR-2 levels were associated with dovitinibmediated antitumor activity including metabolic response and PFS.
Secondary resistant mutations were readily detectable in ctDNA by BEAMing and the majority of these mutations are located in the activation loop.
The presence of secondary KIT mutations in serum-derived ctDNA was significantly associated with reduced OS.
